New number of shares and votes in Moberg Pharma AB (publ)

Report this content

STOCKHOLM, May 29th, 2020, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510. The 370,000 newly issued shares are held by the company to secure its commitments under incentive programmes.

As per 29 May 2020, the total number of shares in Moberg Pharma AB (publ) amounts to 19,223,510. All shares are common shares. The total number of votes are 19,223,510. The increase in the number of shares and votes results from an issue of 370,000 class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares. As per 29 May 2020 the company holds 554 746 common shares. The shares are intended to ensure fulfilment of commitments under incentive programmes.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 29 May 2020 at 8:00 am CET.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with ongoing phase 3 studies covering more than 800 patients. Topline results from the North American study are now available, followed by results from the European study expected by the end of the second quarter 2020. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on Nasdaq Stockholm (OMX: MOB).

Tags: